Globus Medical, Inc. (GMED)
- Previous Close
51.27 - Open
51.08 - Bid 51.83 x 800
- Ask 51.84 x 800
- Day's Range
51.19 - 51.99 - 52 Week Range
43.39 - 62.88 - Volume
109,922 - Avg. Volume
1,044,946 - Market Cap (intraday)
7.004B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
48.36 - EPS (TTM)
1.07 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
61.46
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
www.globusmedical.comRecent News: GMED
Performance Overview: GMED
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GMED
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GMED
Valuation Measures
Market Cap
6.94B
Enterprise Value
6.94B
Trailing P/E
47.92
Forward P/E
19.08
PEG Ratio (5yr expected)
1.74
Price/Sales (ttm)
3.75
Price/Book (mrq)
1.74
Enterprise Value/Revenue
4.43
Enterprise Value/EBITDA
20.03
Financial Highlights
Profitability and Income Statement
Profit Margin
7.83%
Return on Assets (ttm)
4.77%
Return on Equity (ttm)
4.21%
Revenue (ttm)
1.57B
Net Income Avi to Common (ttm)
122.87M
Diluted EPS (ttm)
1.07
Balance Sheet and Cash Flow
Total Cash (mrq)
517.79M
Total Debt/Equity (mrq)
13.04%
Levered Free Cash Flow (ttm)
-346.92M
Research Analysis: GMED
Company Insights: GMED
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: GMED
GMED: Lowering target price to $41.00
GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetGMED: Raising target price to $43.00
GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetGMED: What does Argus have to say about GMED?
GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetGMED: Lowering target price to $41.00
GLOBUS MEDICAL INC - A has an Investment Rating of SELL; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target